Journal article

Standard-Dose Osimertinib in EGFR-Mutated Non–Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease

Luke S McLean, Wasek Faisal, Sagun Parakh, Steven C Kao, Craig R Lewis, Melvin T Chin, Mark Voskoboynik, Malinda J Itchins, Ross R Jennens, Adam R Broad, Tessa A Morris, Benjamin J Solomon

JCO Precision Oncology | American Society of Clinical Oncology (ASCO) | Published : 2021


PURPOSE Leptomeningeal disease (LMD) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma is associated with a poor prognosis and limited treatment options. Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor with confirmed CNS penetration. This study reports on outcomes of patients with EGFR-mutated non–small-cell lung cancer who developed LMD and were subsequently treated with osimertinib. METHODS We identified patients treated with osimertinib 80 mg PO daily under a compassionate access scheme across nine tertiary Australian institutes between July 2017 and July 2020. Patient demographics, tumor characteristics, and treatment history were collected. Me..

View full abstract